In the early 1960's Wistar's scientists began to devote increasing efforts to cancer research. Significant advances were made in tumor virology, carcinogenesis, and molecular biology, led by Drs. Vittorio Defendi, Barbara Knowles, and Carlo M. Croce. In recognition of this increased focus on cancer research, Wistar received a Cancer Center Support Grant (CCSG) and was designated by the National Cancer Institute (NCI) as a federally designated Cancer Center in 1972, specializing in basic research. The Institute has had over 40 years of continuous funding from the NCI with a history of significant advances in cancer genetics, cancer biology, and tumor immunology and virology. The Cancer Center receives $11,582,210 of total funding from the NCI, amounting to over 50% of total federal peer reviewed funding, attesting to the cancer focus of the Center. The Cancer Center is organized to develop and support Cancer Center members, research programs, and the Shared Facilities. Each laboratory in the Cancer Center is headed by a principal investigator who has an active research program at the Institute. The Cancer Center is headed by a Director and two Deputy Directors. Dr. Kaufman is the Director of the Cancer Center and has ultimate control of space, financial resources, appointments, and staff positions in the Cancer Center. Drs. Frank J. Rauscher III and Meenhard Herlyn serve as the Cancer Center's Deputy Directors. Dr. Rauscher's primary responsibility is promotion of basic science research, while Dr. Herlyn provides leadership in the area of translational research. The Cancer Center has made significant progress over the course of the last funding period with recruitment of 12 scientists, renovation of Cancer Center laboratory space, extensive renovation and investment in new instrumentation in shared facilities, and development of resources and plans to expand laboratory facilities. Most importantly, we have made major scientific advances in the fields of cancer genetics, cancer biology, computational biology, and tumor immunology.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Program Officer
Silkensen, Shannon M
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Wistar Institute
United States
Zip Code
Duperret, Elizabeth K; Trautz, Aspen; Stoltz, Regina et al. (2018) Synthetic DNA-Encoded Monoclonal Antibody Delivery of Anti-CTLA-4 Antibodies Induces Tumor Shrinkage In Vivo. Cancer Res 78:6363-6370
Papasavvas, Emmanouil; Lada, Steven M; Joseph, Jocelin et al. (2018) Analytical ART interruption does not irreversibly change pre-interruption levels of cellular HIV. AIDS :
Kugel 3rd, Curtis H; Douglass, Stephen M; Webster, Marie R et al. (2018) Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations. Clin Cancer Res 24:5347-5356
Reyes-Uribe, Patricia; Adrianzen-Ruesta, Maria Paz; Deng, Zhong et al. (2018) Exploiting TERT dependency as a therapeutic strategy for NRAS-mutant melanoma. Oncogene 37:4058-4072
Bhattacharjee, Souvik; Coppens, Isabelle; Mbengue, Alassane et al. (2018) Remodeling of the malaria parasite and host human red cell by vesicle amplification that induces artemisinin resistance. Blood 131:1234-1247
Fukumoto, Takeshi; Park, Pyoung Hwa; Wu, Shuai et al. (2018) Repurposing Pan-HDAC Inhibitors for ARID1A-Mutated Ovarian Cancer. Cell Rep 22:3393-3400
Thangavel, Chellappagounder; Boopathi, Ettickan; Liu, Yi et al. (2018) Therapeutic Challenge with a CDK 4/6 Inhibitor Induces an RB-Dependent SMAC-Mediated Apoptotic Response in Non-Small Cell Lung Cancer. Clin Cancer Res 24:1402-1414
Lu, Yunqi; Hu, Zhongyi; Mangala, Lingegowda S et al. (2018) MYC Targeted Long Noncoding RNA DANCR Promotes Cancer in Part by Reducing p21 Levels. Cancer Res 78:64-74
Duperret, Elizabeth K; Wise, Megan C; Trautz, Aspen et al. (2018) Synergy of Immune Checkpoint Blockade with a Novel Synthetic Consensus DNA Vaccine Targeting TERT. Mol Ther 26:435-445
Duperret, Elizabeth K; Liu, Shujing; Paik, Megan et al. (2018) A Designer Cross-reactive DNA Immunotherapeutic Vaccine that Targets Multiple MAGE-A Family Members Simultaneously for Cancer Therapy. Clin Cancer Res 24:6015-6027

Showing the most recent 10 out of 741 publications